- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946874
Dexamethasone Added to Transversalis Fascia Plane Block in Inguinal Hernia Repair
Perineural Dexamethasone as an Adjuvant to Bupivacaine in Transversalis Fascia Plane Block for Open Inguinal Hernia Repair: A Randomized, Controlled, Double-Blind Study
Transversalis fascia plane (TFP) block is an ultrasound-guided abdominal wall block used for postoperative analgesia after inguinal hernia repair. Perineural dexamethasone prolongs analgesia in peripheral nerve blocks, but its efficacy in fascial plane blocks, where the injectate reaches the nerves by diffusion, is uncertain, and no placebo-controlled randomized trial has addressed this question for the TFP block. This prospective, randomized, controlled, double-blind trial will evaluate whether adding 4 mg dexamethasone to bupivacaine in a TFP block prolongs the time to first analgesic request and reduces rescue analgesic consumption in adult patients undergoing elective unilateral open inguinal hernia repair under spinal anesthesia. Sixty-four patients will be randomized 1:1 to bupivacaine + dexamethasone or bupivacaine + saline.
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients scheduled for elective unilateral open inguinal hernia repair under spinal anesthesia (15 mg hyperbaric bupivacaine 0.5%) will be randomized to two groups (n=32 each) using computer-generated random numbers (Research Randomizer). At the end of surgery, a unilateral ultrasound-guided TFP block will be performed (in-plane technique, 21G 100 mm needle, between the transversus abdominis muscle and the transversalis fascia, between the midaxillary line and the iliac crest).
Group D: 20 mL 0.25% bupivacaine + 4 mg (1 mL) dexamethasone. Group K (control): 20 mL 0.25% bupivacaine + 1 mL saline. Total volume is 21 mL in both groups. Study solutions are prepared by an independent anesthesia technician not otherwise involved in the study. The block performer, the postoperative assessor and the patient are blinded to group allocation.
All patients receive 1 g IV paracetamol 20 minutes before the end of surgery and 1000 mg IV paracetamol every 8 hours postoperatively. Rescue analgesia: 50 mg IV dexketoprofen for NRS ≥4 or on patient request; if NRS remains ≥4, 50 mg IV tramadol. Pain (NRS) is assessed at rest and during movement at 2, 4, 8, 12 and 24 hours. Recovery quality is assessed with the Turkish version of the QoR-15 (QoR-15T) preoperatively and at 24 hours. Block-related complications are monitored.
Sample size (G*Power 3.1.9.4; d=0.75, alpha 0.05 two-tailed, power 80%) was 29 per group; increased by 10% for dropouts to 32 per group (N=64). Data will be analyzed with SPSS 23.0 (independent t-test or Mann-Whitney U for continuous variables, chi-square or Fisher's exact test for categorical variables; p<0.05).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fatih Balcı
- Phone Number: +90 545 864 76 57
- Email: fatihbalci05@gmail.com
Study Locations
-
-
Sivas
-
Merkez, Sivas, Turkey (Türkiye), 58050
- Sivas Numune Hospital, Department of Anesthesiology and Reanimation, Sivas, Turkey
-
Contact:
- Fatih Balcı
- Phone Number: +905458647657
- Email: fatihbalci05@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- ASA physical status I-II
- Elective unilateral open inguinal hernia repair under spinal anesthesia
- Written informed consent
Exclusion Criteria:
- Infection at the block site
- Known allergy or contraindication to local anesthetics or dexamethasone
- History of bleeding diathesis or coagulopathy
- Uncontrolled diabetes mellitus
- Severe cognitive impairment preventing pain assessment (NRS)
- Refusal or inability to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Grup D
TFP block with 20 mL 0.25% bupivacaine + 4 mg (1 mL) dexamethasone (total 21 mL) at the end of surgery. |
4 mg (1 mL) added to bupivacaine in the TFP block. 20 mL 0.25% bupivacaine for the TFP block. |
|
Placebo Comparator: Grup K
TFP block with 20 mL 0.25% bupivacaine + 1 mL 0.9% saline (total 21 mL) at the end of surgery. |
20 mL 0.25% bupivacaine for the TFP block. 1 mL 0.9% saline added to bupivacaine as placebo. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to first analgesic request
Time Frame: 24 hours postoperatively
|
Time in minutes from completion of the TFP block to the first request for rescue analgesia (dexketoprofen 50 mg IV), given for NRS ≥4 or on patient request. |
24 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VAS pain score at rest
Time Frame: 2, 4, 8, 12 and 24 hours postoperatively
|
Pain intensity at rest measured with the Visual Analog Scale (VAS, 0 = no pain, 10 = worst imaginable pain). |
2, 4, 8, 12 and 24 hours postoperatively
|
|
VAS pain score during movement
Time Frame: 2, 4, 8, 12 and 24 hours postoperatively
|
Pain intensity during movement (coughing or 30° leg raise) measured with the VAS (0-10). |
2, 4, 8, 12 and 24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Celik HK, Tulgar S, Buk OF, Koc K, Unal M, Genc C, Suren M. Comparison of the analgesic efficacy of the ultrasound-guided transversalis fascia plane block and erector spinae plane block in patients undergoing open inguinal hernia repair under spinal anesthesia. Korean J Anesthesiol. 2024 Apr;77(2):255-264. doi: 10.4097/kja.23404. Epub 2024 Jan 8.
- Hebbard PD. Transversalis fascia plane block, a novel ultrasound-guided abdominal wall nerve block. Can J Anaesth. 2009 Aug;56(8):618-20. doi: 10.1007/s12630-009-9110-1. Epub 2009 Jun 4. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Postoperative Complications
- Pathologic Processes
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Organic Chemicals
- Polycyclic Compounds
- Anilides
- Amides
- Aniline Compounds
- Amines
- Inorganic Chemicals
- Chlorine Compounds
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Pregnadienetriols
- Sodium Compounds
- Chlorides
- Hydrochloric Acid
- Dexamethasone
- Bupivacaine
- Sodium Chloride
Other Study ID Numbers
- 2026-05/33 07.05.2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
upon reasonable request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.